In an overweight adult who regularly uses kratom, is the elevated alanine aminotransferase (ALT) most likely due to non‑alcoholic fatty liver disease from obesity or to kratom‑induced hepatotoxicity?

Elevated ALT in an Overweight Adult Using Kratom

In an overweight adult with regular kratom use and elevated ALT, non-alcoholic fatty liver disease (NAFLD) from obesity is the overwhelmingly more likely cause, given that NAFLD affects 70% of individuals with obesity, whereas kratom-induced hepatotoxicity remains rare with only isolated case reports in the literature. 12

Epidemiologic Context

NAFLD is the most common cause of mildly elevated ALT in developed countries, accounting for the majority of mild aminotransferase elevations. 13 The prevalence data strongly favor NAFLD as the primary etiology:

• General population NAFLD prevalence: 20–30% 12
• In individuals with obesity: approximately 70% 12
• In individuals with diabetes: approximately 90% 12

In contrast, kratom-induced hepatotoxicity is documented only in rare case reports, with the published literature containing fewer than a handful of histologically confirmed cases. 45

Distinguishing Features: NAFLD vs. Kratom Hepatotoxicity

NAFLD Pattern

**The typical NAFLD presentation shows an AST:ALT ratio <1**, whereas alcohol-induced fatty liver disease generally shows AST:ALT >2. 11 Key metabolic risk factors include:

• Central obesity (waist circumference >40 inches in men, >35 inches in women) 22
• Hypertension (BP ≥130/≥85 mm Hg) 22
• Dyslipidemia (triglycerides ≥150 mg/dL, HDL <40 mg/dL in men or <50 mg/dL in women) 22
• Impaired fasting glucose (≥100 mg/dL) 22

ALT levels in NAFLD are typically mildly elevated (<5 times the upper reference limit), though up to 50% of NAFLD patients may have normal ALT levels. 32

Kratom Hepatotoxicity Pattern

Kratom-induced liver injury presents as acute cholestatic hepatitis with a distinct biochemical signature:

• Marked hyperbilirubinemia (total bilirubin 23.2–28.9 mg/dL in reported cases) 4
• Mild elevation of aminotransferases (ALT 389 U/L, AST 220 U/L) 5
• Elevated alkaline phosphatase (304 U/L) 5
• Cholestatic pattern with dark urine and light-colored stools 45
• Histology showing zone 3 hepatocellular and canalicular cholestasis, focal hepatocyte dropout, and bile duct injury 5

A critical distinguishing feature is that kratom hepatotoxicity is predominantly cholestatic rather than hepatocellular, with jaundice being the presenting symptom rather than isolated aminotransferase elevation. 45

Diagnostic Algorithm

Step 1: Assess Metabolic Risk Factors

Evaluate for features of metabolic syndrome:

• Body mass index and waist circumference 22
• Blood pressure measurement 22
• Fasting lipid panel (triglycerides, HDL-cholesterol) 22
• Fasting plasma glucose 22

If ≥2 metabolic risk factors are present in an overweight individual, the pre-test probability of NAFLD exceeds 70%. 23

Step 2: Calculate AST:ALT Ratio

• AST:ALT <1 strongly suggests NAFLD 11
• AST:ALT >2 suggests alcohol-induced liver disease 11

Step 3: Assess for Cholestatic Features

Check for evidence of cholestasis that would suggest kratom hepatotoxicity:

• Total bilirubin level (markedly elevated in kratom injury) 45
• Alkaline phosphatase (elevated in cholestatic pattern) 5
• Clinical jaundice (present in kratom cases) 45

If bilirubin and alkaline phosphatase are normal or only mildly elevated, kratom hepatotoxicity is highly unlikely. 45

Step 4: Exclude Other Secondary Causes

A thorough workup must rule out competing causes of steatosis: 22

• Hepatitis B surface antigen 22
• Hepatitis C antibody 22
• Alcohol consumption history (≥14 drinks/week for women, ≥21 drinks/week for men) 22
• Medication review for hepatotoxic agents 22
• Hemochromatosis screening (ferritin, transferrin saturation) 22

Step 5: Fibrosis Risk Stratification

Calculate FIB-4 score as the first-line non-invasive test for fibrosis risk: 222

• FIB-4 <1.3 indicates low risk of advanced fibrosis 22
• FIB-4 >1.3 warrants second-level testing with vibration-controlled transient elastography (VCTE) or Enhanced Liver Fibrosis (ELF) test 222

For patients >65 years, use higher FIB-4 cutoffs (1.9–2.0) to determine advanced fibrosis. 2

Recent Kratom Safety Data

A 2026 randomized controlled trial in 116 healthy volunteers receiving up to 53.2 mg mitragynine daily for 15 days found that increased ALT was among the most common treatment-emergent adverse events after multiple doses, but no serious adverse events or deaths occurred. 6 This suggests kratom can cause mild transaminase elevations in a dose-dependent manner, but severe cholestatic hepatotoxicity remains rare.

A 2025 meta-analysis of 1,458 adults found kratom use was associated with lower BMI, lower LDL-cholesterol, lower triglycerides, and higher HDL-cholesterol, suggesting potential metabolic benefits rather than metabolic harm. 7 However, this does not exclude rare idiosyncratic hepatotoxicity.

Clinical Pitfalls

Common Pitfall #1: Assuming Normal ALT Excludes NAFLD

Normal ALT levels do not rule out NAFLD or significant fibrosis—up to 50% of NAFLD patients (including those with stage F2 fibrosis) may have ALT <40 U/L. 32 The American Association of Clinical Endocrinology defines elevated ALT as >30 U/L in men and >25 U/L in women. 22

Common Pitfall #2: Overlooking the Cholestatic Pattern

Kratom hepatotoxicity presents with marked jaundice and cholestatic biochemistry, not isolated mild ALT elevation. 45 If bilirubin is normal, kratom is unlikely to be the cause.

Common Pitfall #3: Failing to Assess Metabolic Syndrome Components

In high-risk groups (obesity, diabetes, metabolic syndrome), the chance of having hepatic steatosis is very high (>70%), allowing risk stratification without mandatory ultrasound confirmation. 23

Management Recommendations

If NAFLD is Confirmed:

• Lifestyle modification targeting 7–10% weight loss is the cornerstone of NAFLD management 2
• Address all metabolic syndrome components: obesity, diabetes, hypertension, dyslipidemia 222
• Repeat ALT and fibrosis assessment in 3–6 months to monitor disease trajectory 2
• Consider referral to hepatology if FIB-4 >1.3 or VCTE suggests advanced fibrosis 22

If Kratom Hepatotoxicity is Suspected:

• Immediate discontinuation of kratom 45
• Consider ursodeoxycholic acid for cholestatic injury 4
• Monitor liver chemistries closely until normalization 45
• Liver biopsy may be warranted if diagnosis is uncertain or if severe cholestatic injury persists 45

Bottom Line

Given the 70% prevalence of NAFLD in obesity versus the rarity of kratom hepatotoxicity, NAFLD is the presumptive diagnosis unless cholestatic features (marked hyperbilirubinemia, elevated alkaline phosphatase, jaundice) are present. 1245 The presence of metabolic risk factors, an AST:ALT ratio <1, and absence of cholestasis strongly support NAFLD as the etiology. 1122